The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult). These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes. An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease. Scope of the Report: The research usually can last 8-10 years, so scale production will occur in 2018. Before then, the Human Micobiome companies have to continue deficit. At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share. The global Human Micobiome market is valued at 170 million USD in 2018 and is expected to reach 610 million USD by the end of 2024, growing at a CAGR of 23.9% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Micobiome. Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%. This report studies the Human Micobiome market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Micobiome market by product type and applications/end industries. Market Segment by Companies, this report covers Vedanta Seres Therapeutics Second Genome Rebiotix ActoGeniX Enterome BioScience AvidBiotics 4D Pharma Research Ltd Enterologics Metabogen Metabiomics Ritter Pharmaceuticals Osel Symberix Miomics Symbiotix Biotherapies MicroBiome Therapeutics LLC Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers Gastrointestinal Tract Human Micobiome Urogenital Tract Human Micobiome Other Market Segment by Applications, can be divided into Treatment Diagnosis
Table of Contents 1 Human Micobiome Market Overview 1.1 Product Overview and Scope of Human Micobiome 1.2 Classification of Human Micobiome by Types 1.2.1 Global Human Micobiome Revenue Comparison by Types (2019-2024) 1.2.2 Global Human Micobiome Revenue Market Share by Types in 2018 1.2.3 Gastrointestinal Tract Human Micobiome 1.2.4 Urogenital Trac
